Specific recognition by a T cell is dictated by a heterodimeric alpha-beta receptor (TCR). Although T cells undergo selection so that reactions with """"""""self"""""""" antigens should not occur, some autoimmune diseases are caused by aberrant T cells that recognize """"""""self"""""""" antigens. Various pathologic conditions have also been associated with the massive T cell stimulation that accompanies infection with superantigens such as bacterial enterotoxins. The inactivation or elimination of only detrimental T cells in these diseases will require the development of reagents that can be used to target specific T cells. Although anti-TCR antibodies have been used in a number of cases to prevent T cell mediated diseases in mice, there are many aspects of such treatments that could be optimized. The ideal reagents will specifically inactivate or eliminate T cell populations at low doses and with no adverse side effects. There is evidence that some side effects may be due to TCR cross-linking by bivalent antibodies and that monovalent antibodies may be more useful in this regard. With this in mind, the proposed studies will engineer monovalent single-chain anti-receptor antibodies (scFv) that will be expressed in E. coli. The scFv proteins will be used in vivo to determine if they can inactivate and/or delete specific T cell populations. The results should provide information on the effect of antibody size and binding affinity in targeting T cells and on the mechanisms involved in T cell inactivation. The system to be used in this proposal involves the alpha-beta TCR from the BALB.B derived CTL clone 2C. The 2C alpha-beta has been expressed in trangenic mice and there is a syngeneic clonotypic monoclonal antibody, 1B2, specific for the 2C alpha-beta and an allogeneic antibody, F23.1, specific for the V-beta region. CTL 2C and T cells from the transgenic mice recognize the Ld alloantigen and SEB/class II complexes. Our lab has engineered and characterized an active 29 kD scFv of the 1B2 antibody that can be purified in large quantities from E. coli inclusion body pellets. This scFv-1B2 will be used in the proposed study, which has three aims: 1) To construct and characterize the scFv of the anti-V-beta8 antibody F23.1. 2) To engineer a higher affinity anti-receptor antibody by linking the scFv-1B2 and scFv-F23.1 genes. As the 1B2 and F23.1 antibodies bind to different epitopes on the same TCR, we will thus test the hypothesis that a high affinity bivalent antibody might be generated by covalent linkage of the two binding sites. 3) To compare the in vivo effectiveness of the scFv-1B2, scFv-F23.1, and bivalent scFv2. In these studies, scFv proteins, Fab fragments, and intact antibodies will be administered to 2C transgenic mice or normal BALB/c mice (F23. I reagents only). Treated animals will be examined for inactivation or deletion of the targeted T cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI035987-04
Application #
2004105
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1994-12-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Finkelman, Fred D (2007) Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 120:506-15;quiz 516-7
Finkelman, Fred D; Rothenberg, Marc E; Brandt, Eric B et al. (2005) Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol 115:449-57; quiz 458
Zhao, Aiping; Morimoto, Motoko; Dawson, Harry et al. (2005) Immune regulation of protease-activated receptor-1 expression in murine small intestine during Nippostrongylus brasiliensis infection. J Immunol 175:2563-9
Strait, Richard T; Morris, Suzanne C; Smiley, Kristi et al. (2003) IL-4 exacerbates anaphylaxis. J Immunol 170:3835-42
Zhao, Aiping; McDermott, Joseph; Urban Jr, Joseph F et al. (2003) Dependence of IL-4, IL-13, and nematode-induced alterations in murine small intestinal smooth muscle contractility on Stat6 and enteric nerves. J Immunol 171:948-54
Madden, Kathleen B; Whitman, Lucia; Sullivan, Carolyn et al. (2002) Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol 169:4417-22
Finkelman, F D; Urban Jr, J F (2001) The other side of the coin: the protective role of the TH2 cytokines. J Allergy Clin Immunol 107:772-80
Shea-Donohue, T; Sullivan, C; Finkelman, F D et al. (2001) The role of IL-4 in Heligmosomoides polygyrus-induced alterations in murine intestinal epithelial cell function. J Immunol 167:2234-9
Urban Jr, J F; Noben-Trauth, N; Schopf, L et al. (2001) Cutting edge: IL-4 receptor expression by non-bone marrow-derived cells is required to expel gastrointestinal nematode parasites. J Immunol 167:6078-81
Morris, S C; Gause, W C; Finkelman, F D (2000) IL-4 suppression of in vivo T cell activation and antibody production. J Immunol 164:1734-40

Showing the most recent 10 out of 24 publications